Following low incidence of respiratory syncytial virus (RSV) infections in 2020 during the COVID-19 pandemic, we noted a resurgence in hospitalised children in spring/summer 2021 following relaxation of public health measures. We compared this outbreak to previous autumn/winter seasons. We found higher weekly case numbers and incidence rates, more cases from urban neighbourhoods with lower socioeconomic status, and similar clinical presentation and severity. Public health implications include the re-evaluation of palivizumab administration and the need for surge capacity planning.
|State||Published - 1 Jul 2021|
- palivizumab administration
- physical distancing
- respiratory syncytial virus (RSV)
ASJC Scopus subject areas
- Public Health, Environmental and Occupational Health